Amit Bar-Or Selected Research

teriflunomide

1/2022	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
1/2022	Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide.
1/2020	Ofatumumab versus Teriflunomide in Multiple Sclerosis.
1/2020	Advances in oral immunomodulating therapies in relapsing multiple sclerosis.
1/2019	Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
4/2015	Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens.
12/2014	Teriflunomide (Aubagio®) for the treatment of multiple sclerosis.
4/2014	Teriflunomide and its mechanism of action in multiple sclerosis.
8/2013	Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.
9/2012	Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Amit Bar-Or Research Topics

Disease

137	Multiple Sclerosis 10/2022 - 11/2002
27	Relapsing-Remitting Multiple Sclerosis 01/2022 - 02/2008
15	Inflammation (Inflammations) 01/2022 - 09/2004
15	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2021 - 01/2005
14	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 03/2003
13	Demyelinating Diseases (Demyelinating Disease) 12/2021 - 03/2003
13	Infections 01/2021 - 10/2006
11	Chronic Progressive Multiple Sclerosis 09/2022 - 09/2004
7	Neuromyelitis Optica (Devic's Disease) 10/2016 - 10/2008
6	Disease Progression 10/2022 - 09/2004
6	COVID-19 01/2022 - 01/2020
6	Neuroinflammatory Diseases 04/2019 - 12/2003
6	Neoplasms (Cancer) 01/2017 - 07/2011
5	Atrophy 01/2022 - 09/2014
5	Acute Disseminated Encephalomyelitis (Postinfectious Encephalomyelitis) 11/2020 - 02/2007
4	Lymphopenia (Lymphocytopenia) 01/2018 - 10/2010
3	Optic Neuritis (Retrobulbar Neuritis) 05/2022 - 04/2016
3	Progressive Multifocal Leukoencephalopathy 03/2015 - 10/2006
2	Ganglion Cysts (Ganglion) 05/2022 - 11/2019
2	Virus Diseases (Viral Diseases) 01/2022 - 01/2020
2	Pain (Aches) 01/2022 - 08/2008
2	Opportunistic Infections (Opportunistic Infection) 11/2019 - 03/2015
2	Atrioventricular Block 11/2019 - 04/2016
2	Neurodegenerative Diseases (Neurodegenerative Disease) 10/2019 - 09/2011
2	Bradycardia 10/2018 - 01/2018
2	Nasopharyngitis 10/2016 - 04/2016
2	Heart Diseases (Heart Disease) 10/2016 - 09/2011
2	Headache (Headaches) 10/2016 - 04/2016
2	Rheumatoid Arthritis 01/2016 - 03/2015
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2016 - 03/2015
2	Immune Reconstitution Inflammatory Syndrome 03/2015 - 01/2014
2	Alzheimer Disease (Alzheimer's Disease) 11/2005 - 08/2003

Drug/Important Bio-Agent (IBA)

19	Dimethyl FumarateIBA 01/2022 - 09/2012
17	AntibodiesIBA 01/2020 - 03/2003
15	Fingolimod Hydrochloride (FTY720)FDA Link 01/2021 - 10/2010
11	CytokinesIBA 01/2020 - 04/2004
10	Myelin-Oligodendrocyte GlycoproteinIBA 10/2022 - 03/2005
10	teriflunomideIBA 01/2022 - 09/2012
9	AntigensIBA 11/2021 - 03/2003
9	ocrelizumabIBA 01/2021 - 11/2011
9	AutoantibodiesIBA 11/2020 - 03/2003
8	Biological ProductsIBA 01/2022 - 05/2006
8	Rituximab (Mabthera)FDA Link 10/2021 - 02/2008
8	Interferon beta-1a FDA Link 11/2019 - 09/2004
7	ozanimodIBA 10/2022 - 04/2016
7	Proteins (Proteins, Gene)FDA Link 10/2022 - 02/2003
7	siponimodIBA 09/2022 - 01/2018
7	GadoliniumIBA 01/2021 - 09/2011
7	Interleukin-10 (Interleukin 10)IBA 04/2019 - 05/2007
6	Sphingosine-1-Phosphate ReceptorsIBA 09/2022 - 04/2016
6	ofatumumab FDA Link 01/2022 - 01/2018
6	Monoclonal AntibodiesIBA 01/2022 - 10/2006
6	Glatiramer Acetate (Copaxone)FDA Link 08/2020 - 11/2002
6	MicroRNAs (MicroRNA)IBA 10/2019 - 01/2012
6	Natalizumab (Tysabri)FDA Link 04/2017 - 05/2006
5	Pharmaceutical PreparationsIBA 12/2021 - 09/2006
4	EpitopesIBA 01/2021 - 01/2008
4	InterferonsIBA 01/2021 - 11/2002
4	Interleukin-6 (Interleukin 6)IBA 03/2015 - 08/2008
3	Immunoglobulin G (IgG)IBA 10/2022 - 10/2008
3	VaccinesIBA 01/2022 - 10/2020
3	Interferon-betaIBA 10/2020 - 09/2006
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 08/2014
3	Matrix Metalloproteinases (MMPs)IBA 01/2020 - 12/2003
3	Oligoclonal BandsIBA 11/2019 - 05/2011
3	Immunoglobulins (Immunoglobulin)IBA 01/2017 - 11/2006
3	Immunoglobulin M (IgM)IBA 03/2015 - 03/2014
3	ChemokinesIBA 07/2011 - 09/2006
3	Myelin Basic ProteinIBA 10/2007 - 02/2003
2	Retinaldehyde (Retinal)IBA 05/2022 - 11/2019
2	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 01/2021
2	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2022 - 08/2013
2	EnzymesIBA 10/2021 - 01/2021
2	laquinimodIBA 01/2020 - 01/2012
2	Minocycline (Cyclops)FDA LinkGeneric 01/2020 - 01/2005
2	Immunoglobulin A (IgA)IBA 04/2019 - 01/2019
2	amiselimodIBA 10/2018 - 10/2016
2	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 10/2018 - 04/2016
2	Transaminases (Aminotransferases)IBA 01/2018 - 09/2012
2	AutoantigensIBA 10/2016 - 01/2008
2	Aquaporins (Water Channels)IBA 10/2016 - 07/2012
2	LipidsIBA 04/2016 - 03/2015
2	FumaratesIBA 01/2016 - 02/2014
2	Lymphotoxin-alpha (Lymphotoxin)IBA 12/2015 - 05/2012
2	Transcription Factors (Transcription Factor)IBA 12/2015 - 03/2014
2	Maraviroc FDA Link 03/2015 - 01/2014
2	Toll-Like Receptors (Toll-Like Receptor)IBA 02/2014 - 08/2005
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2014 - 08/2008
2	Peptides (Polypeptides)IBA 11/2013 - 02/2007
2	CalciumIBA 03/2013 - 09/2011
2	LigandsIBA 03/2013 - 08/2005
1	Type I Tumor Necrosis Factor ReceptorsIBA 10/2022
1	ParvalbuminsIBA 10/2022

Therapy/Procedure

45	Therapeutics 01/2022 - 12/2003
5	Immunotherapy 04/2021 - 01/2016
3	Hematopoietic Stem Cell Transplantation 01/2020 - 03/2013
3	Drug Therapy (Chemotherapy) 01/2020 - 03/2013
3	Transplantation 08/2016 - 04/2010
2	Immunomodulation 01/2022 - 01/2020
2	Mesenchymal Stem Cell Transplantation 01/2018 - 04/2010